Ovarian Stimulation in Patients With Cancer: Impact of Letrozole and BRCA Mutations on Fertility Preservation Cycle Outcomes.

about

Ovarian Stimulation in Patients With Cancer: Impact of Letrozole and BRCA Mutations on Fertility Preservation Cycle Outcomes.

Item

http://www.wikidata.org/entity/Q48032298

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Ovarian Stimulation in Patient ...... y Preservation Cycle Outcomes.

@en

Ovarian Stimulation in Patient ...... y Preservation Cycle Outcomes.

@nl

type

Item

label

Ovarian Stimulation in Patient ...... y Preservation Cycle Outcomes.

@en

Ovarian Stimulation in Patient ...... y Preservation Cycle Outcomes.

@nl

prefLabel

Ovarian Stimulation in Patient ...... y Preservation Cycle Outcomes.

@en

Ovarian Stimulation in Patient ...... y Preservation Cycle Outcomes.

@nl

P1476

Ovarian Stimulation in Patient ...... y Preservation Cycle Outcomes.

@en

P2093

Fred Moy

http://www.w3.org/2001/XMLSchema#string

Giuliano Bedoschi

http://www.w3.org/2001/XMLSchema#string

Kutluk Oktay

http://www.w3.org/2001/XMLSchema#string

Volkan Emirdar

http://www.w3.org/2001/XMLSchema#string

Volkan Turan

http://www.w3.org/2001/XMLSchema#string

P2860

Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks

BRCA Mutations, DNA Repair Deficiency, and Ovarian Aging

Recent advances in oocyte and ovarian tissue cryopreservation and transplantation

Cancer statistics, 2012

Premature menopause in patients with BRCA1 gene mutation

Impairment of BRCA1-related DNA double-strand break repair leads to ovarian aging in mice and humans

Anti-Müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations

Letrozole, Gonadotropin, or Clomiphene for Unexplained Infertility

Triggering final oocyte maturation with gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation: an extended experience.

Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update.

P304

26-32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1933719117728800

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28874104

http://www.w3.org/2001/XMLSchema#string